IFNB1 and myeloid sarcoma: MS patients belonged to three clinical subtypes (32 RR, 20 SP and 6 PP), and were treated in 55% of cases with various disease modify therapies (interferon beta-1, natalizumab, glatiramer acetate, fingolimod, azathioprine, and mitoxantrone).